Discover a world of educational opportunities to support your lifelong learning
RACGP offer courses and events to further develop the knowledge you need to develop your GP career
2022 RACGP curriculum and syllabus
for Australian general practice
The Abuse and violence: working with our patients in general practice provides the best-available current evidence for GPs
Stay up-to-date with the latest information and resources on the COVID-19 vaccine rollout.
Download the Standards for general practice (5th edition) - a benchmark for quality care and risk management in Australian general practices
Coronavirus (COVID-19) resources for general practitioners
Advice and guidelines for GPs and practice teams to help protect general practice information systems
Video consultations can provide convenient and accessible healthcare delivery
Read all of the RACGP reports and submissions on various healthcare topics
Read all of the RACGP position statements on various healthcare topics
Join our RACGP Facebook groups
Guideline for the management of knee and hip osteoarthritis
We are unable to recommend either for or against the use of topical NSAIDs for people with knee and/or hip osteoarthritis (OA). It might be reasonable to trial topical NSAIDs for a short period then discontinue use if not effective. Clinicians also need to monitor and capture the adverse effects along with its use.
Conditional (neutral) recommendation
Topical NSAIDs are applied to unbroken skin where there is pain as gels, creams, sprays or plasters. Topical NSAIDs penetrate the skin, enter tissues or joints, and reduce processes that are causing pain in the tissue. Drug levels in the blood with topical NSAIDs are much lower than with the same drug taken by mouth.
The effectiveness of topical NSAID application in OA is variable. Generally, the benefit is small, but the risk of harm is also small. Similar to oral NSAIDs, a judicious trial of topical NSAIDs may be considered as an adjunctive treatment for the short term (several weeks). If unhelpful, topical NSAIDs should be ceased. Regarding adjunctive use, it should be noted that current evidence found that combining a topical NSAID with an oral NSAID confers no additional therapeutic benefit over either agent used alone, but it does increase the number of adverse events.100
Usually, adverse events from topical NSAIDs agents are minimal, but there is mild toxicity because of local skin reactions.
We suggest not offering topical capsaicin for people with knee OA.
Conditional against recommendation
We are unable to recommend either for or against the use of topical capsaicin for people with hip OA.
Capsaicin is the neurotoxin of hot chilli peppers. It binds selectively to the vanilloid compound receptor (Transient Receptor Potential Vanilloid 1 [TRPV1]) of type C afferent fibres, and increases P substance in synaptic cleft.101 While first applications of capsaicin are associated with a burning sensation over the applied surface, with continued use, persistent desensitisation and analgesia occurs because of P substance neural depletion, and reversible and selective destruction of primary afferent fibres.101
Evidence from one trial demonstrated that 0.025% of topical capsaicin had small effects of pain relief in people with knee OA (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document). It is uncertain whether individuals with multi-joint OA or with relevant comorbidities will benefit from capsaicin. The principle benefit of capsaicin is in neuropathic pain, which is not the major pain source in knee or hip OA. Similar to other topical analgesia, the topical application process is very regime orientated, and local irritation side effects can be detrimental. These issues often outweigh possible benefits to individuals.
Mild application site burning was the most common adverse event associated with the topical use of capsaicin (35–100%), but rapidly ameliorates with continuing use. There have been no reports of systemic toxicity with the use of topical capsaicin in OA.
It may be appropriate to offer duloxetine for some people with knee and/or hip OA.
Conditional for recommendation
The imbalance of serotonin and norepinephrine systems within the central pain pathways have been implicated in the development and maintenance of central sensitisation, and associated with chronic pain in OA. Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) with central nervous system activity. Its analgesic efficacy in central pain is putatively related to its influence on descending inhibitory pain pathways. Research has found it has a beneficial effect on pain associated with diabetic neuropathy, fibromyalgia, low back pain and OA.
In the three trials reviewed, significant response and moderate effects in knee pain (standardised mean difference [SMD] 0.43) and function (SMD 0.45) were found over 13–16 weeks at doses of 60/120 mg (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document). However, most study participants were also already using NSAIDs and paracetamol. The use of duloxetine for knee OA adjunctively with NSAIDs, thus reducing the usage of NSAIDs and paracetamol, would be clinically useful to reduce adverse events.
In addition, results differed as to whether significant reduction in depression symptoms was needed for analgesic impact. There is no direct randomised controlled trial (RCT) evidence for hip OA; thus, using knee OA data to extrapolate to hip or other OA requires additional caution.
Duloxetine currently does not have an indication via the Therapeutic Goods Administration (TGA) for OA, and should be considered as an investigational medication only.
Among the participants in the three included RCTs, treatment with duloxetine was well tolerated, with the majority of adverse events being of mild or moderate intensity (eg constipation, nausea, hyperhidrosis, cough, myalgia, arthralgia, palpitations).
Note: subsequent to preparing the grade tables and developing the recommendations, we became aware that one of the studies cited, that by Abou-Raya et al, has been retracted. The recent meta-analysis on duloxetine, which does not include the Abou-Raya study, shows little heterogeneity and remarkable consistency with the effect estimates that we have found.
We do not recommend offering doxycycline for people with knee and/or hip OA
Strong against recommendation
Very low (hip)
Doxycycline is a tetracycline-class antibiotic agent. Besides being an antimicrobial agent, it is a metalloproteinase inhibitor, and inhibits the collagenase that cleaves collagen type IX that is present in articular cartilage.104
Preclinical research and earlier human studies indicated doxycycline might be useful in managing symptomatic knee OA. However, current evidence found that doxycycline did not reduce the mean severity of joint pain, although pain scores in both treatment groups were low at baseline and remained low throughout the trial, which may suggest the presence of a floor effect. Despite the small benefit (SMD 0.15 mm) in joint space narrowing, it is outweighed by medication harms (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document).
There is no RCT of doxycycline for hip OA, thus using knee OA data to extrapolate to hip or other OA requires additional caution. Doxycycline currently does not have an indication via the TGA for OA, and should be considered as an investigational medication only.
Adverse events that occurred significantly more frequently in the doxycycline group than the placebo group were restricted to recognised side effects of doxycycline (ie monilial vaginitis, sun sensitivity, nonspecific gastrointestinal symptoms). However, only a small proportion of subjects reporting doxycycline-related side effects discontinued the study medication prematurely. Subjects in the active treatment group reported fewer urinary tract infections, and there was a trend toward fewer upper respiratory tract infections in the doxycycline group than the placebo group.
Did you know you can now log your CPD with a click of a button?
Administrative-report.pdf (PDF 2.76 MB)
Algorithm-Holistic-assessment-diagnosis-and-management-of-knee-and-hip-osteoarthritis.pdf (PDF 0.05 MB)
Guideline-for-the-management-of-knee-and-hip-osteoarthritis-2nd-ed-Appendix-1.pdf (PDF 0.04 MB)
Guideline-for-the-management-of-knee-and-hip-osteoarthritis-2nd-ed-Appendix-2.pdf (PDF 0.05 MB)
Implementation-plan.pdf (PDF 1.79 MB)
Public-consultation-summary.pdf (PDF 0.29 MB)
Technical-document.pdf (PDF 5.79 MB)